Chiral Technologies, Inc. Acquires Diffinity Genomics

WEST CHESTER, Pa., Aug. 4, 2015 /PRNewswire/ -- Chiral Technologies, part of DAICEL CORPORATION, the global market leader in enantioselective chromatography, is pleased to announce the acquisition of the assets of Diffinity Genomics^® of West Henrietta, N.Y.

Diffinity Genomics has developed novel technology for the purification of nucleic acids, which formed the foundation for their products in DNA purification markets. The Diffinity RapidTip^® technology provides a method for rapid purification of amplified DNA fragments from Polymerase Chain Reaction (PCR) in a single step.

“The innovative, patented purification technology from Diffinity was a perfect choice for our expansion in the bio-separation/purification marketspace,” commented Joseph Barendt, Ph.D., COO of Chiral Technologies, Inc.

As a new business unit of Chiral Technologies, Diffinity’s product portfolio demonstrates Chiral Technologies’ commitment to providing the health sciences industry with innovative separation technologies and ensures our customers will have access to new opportunities in DNA purification.

Joseph Marasco, Ph.D., CEO of Diffinity Genomics, stated: “We are very pleased to become part of Chiral Technologies. We are confident that this is an ideal fit with Chiral Technologies as a multinational development partner to commercialize Diffinity’s unique technologies.”

Mike Riedlinger, one of Diffinity’s co-founders and board member, stated: “We’d like to express our thanks to Dr. Joseph Marasco for all of his contributions to the company since he joined in 2012. As CEO, Joe played a critical role in finding the right partner and then managing the acquisition and operation of the company to its successful outcome.”

Upon the successful completion of the acquisition, Dr. Marasco will leave Diffinity Genomics to pursue other interests.

About Chiral Technologies, Inc.
Chiral Technologies, the global leader in enantioselective chromatography, serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. The company also provides analytical method development and custom separation services.

About Diffinity Genomics
Diffinity Genomics is a Western NY life science company with technologies that enable the development of single-use disposable products for medical, industrial and research applications in DNA purification markets.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chiral-technologies-acquires-diffinity-genomics-300122234.html

SOURCE Chiral Technologies, Inc.